YOUNES, Ramy
 Distribuzione geografica
Continente #
NA - Nord America 4.320
AS - Asia 3.641
EU - Europa 2.533
SA - Sud America 256
OC - Oceania 82
AF - Africa 66
Continente sconosciuto - Info sul continente non disponibili 5
Totale 10.903
Nazione #
US - Stati Uniti d'America 3.945
CN - Cina 2.148
IT - Italia 591
SG - Singapore 300
CA - Canada 291
JP - Giappone 265
DE - Germania 259
SE - Svezia 235
GB - Regno Unito 233
IN - India 205
IE - Irlanda 193
FR - Francia 182
ES - Italia 159
BR - Brasile 154
KR - Corea 112
TW - Taiwan 109
UA - Ucraina 108
HK - Hong Kong 106
MX - Messico 80
AU - Australia 77
GR - Grecia 76
VN - Vietnam 76
ID - Indonesia 71
AT - Austria 67
TR - Turchia 64
PL - Polonia 57
FI - Finlandia 47
NL - Olanda 46
BE - Belgio 41
DK - Danimarca 41
EG - Egitto 41
RU - Federazione Russa 40
IR - Iran 36
CH - Svizzera 31
PT - Portogallo 28
CO - Colombia 27
AR - Argentina 26
IL - Israele 25
SA - Arabia Saudita 24
TH - Thailandia 23
RO - Romania 22
CL - Cile 21
PH - Filippine 20
PE - Perù 18
BG - Bulgaria 14
NO - Norvegia 11
CZ - Repubblica Ceca 9
HU - Ungheria 9
MY - Malesia 9
HR - Croazia 8
EC - Ecuador 7
MO - Macao, regione amministrativa speciale della Cina 7
AE - Emirati Arabi Uniti 6
BD - Bangladesh 6
CV - Capo Verde 6
JO - Giordania 6
EU - Europa 5
KE - Kenya 5
LB - Libano 5
LT - Lituania 5
NZ - Nuova Zelanda 5
IQ - Iraq 4
MA - Marocco 4
PK - Pakistan 4
RS - Serbia 4
BY - Bielorussia 3
LU - Lussemburgo 3
MK - Macedonia 3
KZ - Kazakistan 2
LV - Lettonia 2
MD - Moldavia 2
OM - Oman 2
PS - Palestinian Territory 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
VE - Venezuela 2
ZA - Sudafrica 2
AZ - Azerbaigian 1
BF - Burkina Faso 1
BO - Bolivia 1
CI - Costa d'Avorio 1
CM - Camerun 1
CR - Costa Rica 1
CU - Cuba 1
CY - Cipro 1
GH - Ghana 1
HN - Honduras 1
MN - Mongolia 1
NG - Nigeria 1
NI - Nicaragua 1
QA - Qatar 1
SC - Seychelles 1
Totale 10.903
Città #
Chandler 386
Beijing 327
Redwood City 253
Ann Arbor 247
Fairfield 245
Shanghai 237
Singapore 236
Ottawa 198
Dublin 188
Santa Clara 175
Ashburn 154
Guangzhou 143
Houston 122
Woodbridge 110
Torino 105
Hangzhou 104
Seattle 103
Wilmington 96
Dearborn 92
Wuhan 85
Nanjing 82
Jacksonville 69
Medford 64
Cambridge 62
Tokyo 61
New York 58
Chengdu 55
Princeton 53
Columbus 52
Taipei 52
Dong Ket 51
Pisa 50
Vienna 50
Turin 49
Jakarta 48
London 47
Nyköping 43
Chongqing 42
Seoul 35
Sydney 33
Villeurbanne 33
Zhengzhou 33
Fremont 32
Central District 30
Changsha 30
Hefei 30
Tianjin 30
Boston 28
Changchun 28
Athens 27
Barcelona 26
Jinan 26
Shenyang 26
Rome 25
San Diego 23
Toronto 23
Chennai 22
Duncan 22
Helsinki 22
Kolkata 22
São Paulo 22
Milan 21
Washington 21
Los Angeles 20
San Mateo 20
Brussels 19
Istanbul 19
Santiago 19
Warsaw 19
Madrid 18
Copenhagen 17
Rochester 17
Norwalk 16
Paris 16
Redmond 16
Rio de Janeiro 16
Cairo 15
Lima 15
Amsterdam 13
Delhi 13
Fortaleza 13
Hong Kong 13
Jeddah 13
Manchester 13
Naples 13
Zhangjiagang 13
Boardman 12
Central 12
Düsseldorf 12
Falls Church 12
Frankfurt am Main 12
San Jose 12
Stockholm 12
Bangkok 11
Buenos Aires 11
Harbin 11
Nanchang 11
Salvador 11
Wenzhou 11
Atlanta 10
Totale 5.790
Nome #
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation 1.490
Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults 1.302
Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease 1.090
NASH in lean individuals 922
A spotlight on pathogenesis, interactions and novel therapeutic options in NAFLD 558
Should we undertake surveillance for HCC in patients with NAFLD? 548
Usefulness of the index of NASH – ION for the diagnosis of steatohepatitis in patients with Non-Alcoholic Fatty Liver: an external validation study 544
Circulating Zonulin is Related to Hepatic Necroinflammation in Patients with Non Alcoholic Fatty Liver Disease 270
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease 230
The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease 190
LIVER DAMAGE CAN BE ASSOCIATED WITH DEREGULATION OF THE DE NOVO LIPOGENESIS PATHWAY IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 180
Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single center retrospective study 175
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease 169
Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection 168
Risk factors for metabolic syndrome after liver transplantation: what has changed over time 139
Insulin secretion and decreased glucose clearance are associated with enhanced fibrogenesis and a high risk of disease progression in non-diabetic patients with Non Alcoholic Fatty Liver Disease 137
In non obese NAFLD increased plasma saturated fatty acids and insulin resistance are metabolic signatures of severity of liver disease 134
Microangiopathic hemolytic anemia caused by a signet-ring cell carcinoma of the intrahepatic bile duct 134
On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases 121
DEREGULATION OF DE NOVO LIPOGENESIS CAN BE ASSOCIATED WITH LIVER DAMAGE IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 115
Bile acids composition modulate insulin resistance in non-diabetic patients with NAFLD 115
The Impact of Metabolic Syndrome on the Outcome of NASH: Cirrhosis, Hepatocellular Carcinoma, and Mortality 112
Altered metabolic profile and adipocyte insulin resistance mark severe liver fibrosis in patients with chronic liver disease 111
Prevalence of patients with non-alcoholic fatty liver disease: from primary care to tertiary centers. The Turin experience 106
Diagnostic accuracy of soluble sCD163 for the detection of severe fibrosis in patients with Non-Alcoholic Fatty Liver Disease 106
Hepatocellular carcinoma and metabolic risk factors in a main reference center in Italy 105
Risk factors for arterial hypertension after liver transplantation 105
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease 103
Comment on helicobacter pylori eradication using metronidazole 102
Integrative hepatic transcriptome analysis identifies biomarkers of non-alcoholic steatohepatitis activity and fibrosis progression 100
Increased Pre-Hepatic Insulin Levels Are Directly Related to Nash, Fibrogenesis and Fibrosis in Non Diabetic NAFLD Patients but Not in Type 2 Diabetes 96
Longitudinal prognostic value of the most common algorithms for fibrosis in non-alcoholic fatty liver disease: An international study in non-cirrhotic, biopsy-proven patients 95
Importance of HLA-B in the sustained virological response in patients with chronic hepatitis C treated with peg-IFN and ribavirin 93
NASH-related liver carcinogenesis is critically affected by hypoxia-inducible factor 2 alpha 93
Clinical Characteristics and Long-Term Outcomes of Lean Caucasian Patients with Non- Alcoholic Fatty Liver Disease. a Longitudinal International Study. 92
Selenoprotein P levels discriminate the degree of hepatic steatosis and are related to the NAS score in patients with non-alcoholic fatty liver disease 90
Metabolic Syndrome after liver transplantation: have risk factors changed over time? 89
Predisposition to diabetes is related to insulin resistance in NAFLD patients and to decreased insulin secretion in HCV patients 88
Risk of developing hepatocellular carcinoma in patients with cirrhosis of viral etiology evaluated by the combination of alphafetoprotein, protein induced by vitamin K absence or antagonist-II and glypican-3 86
Epidemiology and Natural History of Patients with NAFLD 84
Application of serum cytokeratin-19 fragments (CYFRA 21-1) in predicting the prognosis of patients with hepatocellular carcinoma 82
Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease 77
Is vitamin B12 serum level involved in the spread of Helicobacter pylori? 68
Risk of developing hepatocellular carcinoma (HCC) in patients with cirrhosis of viral etiology evaluated by the association of alpha-fetoprotein (AFP), protein induced by vitamin K absence or antagonist-II (PIVKA-II) and glypican-3 (GPC-3) 61
Ductular reaction predicts the progression of non-alcoholic fatty liver disease 60
The long-term impact of baseline PNPLA3 genotyping in patients with NAFLD. A longitudinal multicentre study 47
Interplay between metabolic derangement, hepatic fibrogenesis and macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease 47
Molecular mechanisms of hepatic fibrosis in chronic liver diseases 45
Liver stiffness measurement by fibroscan predicts the occurrence of liver-related events and death in patients with NAFLD-related compensated advanced chronic liver disease 43
Cross-Sectional and Longitudinal Performance of Non-Invasive Tests of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease 34
Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease 10
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis 9
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis 9
CARATTERISTICHE CLINICHE E VARIANTI GENETICHE DEI PAZIENTI CON STEATOEPATITE NON ALCOLICA E BMI INFERIORE A 25 (“LEAN NASH”) 8
Totale 11.187
Categoria #
all - tutte 24.441
article - articoli 0
book - libri 0
conference - conferenze 7.177
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.618


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020650 0 0 0 0 0 0 0 116 155 173 119 87
2020/20211.976 101 131 113 135 166 159 187 177 211 258 144 194
2021/20222.114 141 188 156 189 194 119 178 158 187 193 248 163
2022/20231.653 148 144 60 123 143 272 130 152 182 88 93 118
2023/20241.648 135 146 155 160 189 153 125 159 57 97 148 124
2024/20251.369 134 142 159 183 380 213 99 59 0 0 0 0
Totale 11.187